Italy· 044648095
NUCALA*1 siringa preriempita SC 40 mg 0,4 ml
A mepolizumab product containing mepolizumab, registered in Italy by GLAXOSMITHKLINE TRAD.SERV.LTD, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Mepolizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC R03DX09 (mepolizumab), each read from that country’s own register.
- This record: Italy
- 8 of them publish a price we can compare per daily dose
Mepolizumab · ATC R03DX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
- Active substance
- Mepolizumab
- Manufacturer
- GLAXOSMITHKLINE TRAD.SERV.LTD
- Country
- Italy (IT)
- ATC code
- R03DX09
- ATC class
- Mepolizumab
- Defined daily dose
- 3.6 mg, P
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic044648095NUCALA*1 siringa preriempita SC 40 mg 0,4 mlEUR 716.99
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- FinlandNucalaGlaxoSmithKline Trading Services Limited
- BelgiumNucala 100 mgGlaxoSmithKline Trading Services
- SpainNUCALA 100 MG POLVO PARA SOLUCION INYECTABLEGlaxosmithkline Trading Services Limited
- IrelandNucala 100 mg powder for solution for injectionGlaxoSmithKline Trading Services Limited
- IcelandNucalaGlaxoSmithKline Trading Services Limited
- NetherlandsNucala 100 mg oplossing voor injectie in voorgevulde penGlaxoSmithKline Trading Services Limited
- PolandNucalaGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cb900d1f-9bc1-4b34-a094-75b4b8622838 GET /v1/drugs/cb900d1f-9bc1-4b34-a094-75b4b8622838?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 716.99,
"source": "aifa",
"currency": "EUR",
"strength": "MEPOLIZUMAB 0,4 ML 40MG 1 UNITA' USO PARENTERALE",
"substance": "Mepolizumab",
"equivalence_group": "NAJ",
"transparency_flag": null
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.